Introduction
Soon after the advent of the Bcr-Abl tyrosine kinase inhibitor (TKI) imatinib mesylate for the treatment of chronic myeloid leukemia (CML) in 2001, it became clear that Philadelphia-positive (Ph+) cells could evolve to elude inhibition. Since the first imatinibresistant cases, point mutations in the kinase domain (KD) of Bcr-Abl were identified [1] [2] [3] [4] [5] [6] that could impair or even totally abrogate imatinib binding. [7] [8] [9] [10] Over the last decade, intensive efforts have been spent in the characterization of the biological and clinical significance of these mutations on one hand, and in the development of novel inhibitors retaining efficacy against as many Bcr-Abl mutant forms as possible, on the other hand. The list of amino acid substitutions detected in imatinib-resistant patients has steadily grown to include more than ninety different ones ( Figure 1 ), although some are definitely more frequent than others. Different mutations have been shown to confer variable degrees of resistance to imatinib. 11 Clinical experience with dasatinib and nilotinib, the second generation TKIs having received market approval so far, has demonstrated that definite, much narrower spectra of mutations retain insensitivity to these agents -and these spectra are nonoverlapping, the T315I being the unique exception. [12] [13] [14] [15] [16] [17] As more and more therapeutic options to choose between for patients who do not achieve an optimal response to imatinib have become accessible, BCR-ABL KD mutation analysis has turned into a more and more useful tool for physicians. Other mechanisms of resistance are known to exist 18 and to not necessarily be mutually exclusive with mutations. Notwithstanding, the knowledge of the Bcr-Abl KD mutation status is a valuable piece of information to be integrated in the decision algorithm aimed at tailoring the best therapeutic strategy for each of these patients -increasing imatinib dose, [19] [20] [21] [22] switching to the second generation TKIs dasatinib or nilotinib, [12] [13] [14] [15] [16] [17] [23] [24] [25] [26] moving to allogeneic stem cell transplantation, 27 or testing an investigational compound. Mutation analysis of the BCR-ABL KD is now being performed in a growing number of laboratories. However, there is still considerable confusion among
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From physicians as to when mutation analysis should be prescribed, which techniques provide the most informative results, and how these results should be interpreted and translated into clinical decisions. Although we are aware that the therapeutic scenario is in continuous evolution and that some issues at present remain controversial, we believe that sufficient information is available to compile a series of recommendations aimed to optimize the use of this test in the context of routine management of CML patients.
Methods
The panel, that comprises all the authors of this manuscript, was appointed by the European LeukemiaNet (ELN) and European Treatment and Outcome Study (EUTOS) and included fourteen among their members with a well-recognized clinical and/or research experience in CML. After critical review of relevant publications and of relevant abstracts presented at the meetings of the American Society of Hematology and of the European Hematology Association up to December 2010, the panel identified and expressed its expert opinion on key issues concerning: 1. when to perform mutation analysis; 2. how to perform it; 3. how to translate results into clinical practice.
When to look for BCR-ABL KD mutations

Imatinib first-line
Before the start of therapy: only in advanced phase patients or in all patients?
BCR-ABL KD mutation analysis is not recommended in newly diagnosed chronic phase (CP) patients. Conversely, it can be performed in the rare cases who are in accelerated phase (AP) or blast crisis (BC) at the time of imatinib start (Table 1) .
BCR-ABL KD mutations are not induced, but simply selected by TKIs. They arise independently and may thus theoretically pre-exist before the start of therapy. 28 In how many cases this actually happens, however, remains to be extensively
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From 6 addressed in large and unselected cohorts of CML patients. So far, evidence of mutations before the start of imatinib therapy has been reported only in some cases with advanced-phase disease, where the genetic instability is known to be high and the accumulation of additional genetic abnormalities is more likely. An initial report analyzed by sequencing four CML patients in blast crisis who had failed to achieve any hematologic response to imatinib and found that imatinib-resistant mutations (T315I and E255K) were already detectable before imatinib start in two cases. 6 Another study investigated the incidence of the eight most frequent Bcr-Abl KD mutations in 66 unselected, imatinib-naïve patients using a highly sensitive technique (allele-specific polymerase chain reaction). 29 No mutation was detected in the 20 patients in chronic phase (CP), whereas 10/27 accelerated phase (AP) and 5/19 blast crisis (BC) patients were positive for mutations (although in several cases the mutant clone was present at very low levels). Mutation analysis is recommended both in case of failure and in case of suboptimal response to imatinib (Table 1) .
From a clinical standpoint, "failure" means that continuing a specific treatment is no longer appropriate since a favourable outcome is unlikely. [32] [33] It has been estimated that, overall, 29% of CP patients with strictly defined failure on first-line imatinib do harbor a Bcr-Abl KD mutation, although differences exist in mutation incidence across different subcategories of 'failure' 34 -in line with the fact that mutations are more frequently involved in acquired resistance rather than in primary resistance.
35
"Suboptimal response" means that the patient may still have a substantial long-term benefit from continuing a specific treatment, but the chances of an optimal outcome are reduced. 33 
32-33
We can expect Bcr-Abl KD mutations to be detectable in a proportion of cases showing an increase in BCR-ABL transcripts. An initial study showed that a more than two-fold increase in BCR-ABL transcript level was associated with the presence of a KD mutation at the time or within three months from the time of first rise in all the patients analyzed. 45 However, this observation could not be confirmed in a subsequent independent study, 46 that proposed that a rise in BCR-ABL transcript level of two-fold or more in at least two consecutive evaluations, rather than a single rise, is a more reliable indicator. It is important to note that variations in the performance of local RQ-PCR assays limit the general applicability of these values.
For all these reasons, it is more reasonable to advise that in patients showing an increase in BCR-ABL transcript level, only a confirmed loss of MMR be the trigger for a mutation analysis.
Dasatinib or nilotinib second-line
The second-generation TKIs dasatinib and nilotinib are approved for the treatment of imatinib-intolerant or -resistant patients. In these patients, the presence or emergence of mutations -the T315I or a few others that are known to be less Hematologic or cytogenetic failure may be caused, or accompanied, by the appearance of a Bcr-Abl KD mutation, whose identification may be important in order to choose whether to switch to another TKI or proceed to allogeneic stem cell transplantation. 27
Dasatinib or nilotinib first-line
The use of dasatinib or nilotinib for the first-line treatment of CML has so far been confined to the context of phase II and phase III clinical trials. [55] [56] [57] [58] [59] In the phase II studies of nilotinib by the GIMEMA CML working party and by the MD Anderson Cancer Center, only two patients relapsed and progressed to blast crisis, and they were found to harbor a T315I and an E255K mutation, respectively. 55-56 The remaining published studies did not detail whether the few relapsed cases were positive for any KD mutation. Indeed, since the two phase III randomized studies [57] [58] have shown that with both dasatinib and nilotinib response dynamics are more rapid, a better assessment of the value of mutation analysis in this setting requires more data and a longer follow-up.
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How to look for BCR-ABL KD mutations
Direct sequencing is the method we recommend for BCR-ABL KD mutation analysis.
Direct sequencing may be combined with denaturing-high performance liquid chromatography (D-HPLC) analysis -wherever this technology is available. D-HPLC is a straightforward and high-throughput tool to pre-screen for sequence variations, resulting in a great reduction of the number of samples that need to be sequenced. D-HPLC and/or direct sequencing are already in use in several laboratories, since they have proven a reliable method for the detection of clinically relevant Bcr-Abl KD mutations. When mutation analysis is performed in one of the specific cases identified in Section 1, and with the techniques recommended in Section 2, a positive result represents an indication for a change in the therapeutic strategy, but the type of mutation matters.
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-in case of a T315I mutation, that is highly resistant to imatinib, dasatinib and nilotinib, there are no pharmacologic opportunities other than investigational compounds in phase I/II clinical development.
-In case of V299L, T315A, or F317L/V/I/C mutations, nilotinib is likely to be more effective than dasatinib.
17,47-54
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-In case of Y253H, E255K/V or F359V/C/I mutations, dasatinib is likely to be more effective than nilotinib. 
Conclusions
Here we aimed to provide recommendations to clinicians on how to best integrate BCR-ABL KD mutation analysis in the routine management of CML patients. We acknowledge that the literature is still not comprehensive enough to base all our recommendations on sound evidence. The reader should therefore be warned that these are mostly based on the expert opinion of the members of this panel.
The cases in which a BCR-ABL KD mutation analysis is recommended are summarized in Table 1 . This is mainly intended for newly diagnosed patients receiving imatinib first-line.
However, results of imatinib second-line in CP patients [78] [79] [80] should be part of this algorithm, as summarized in Table 2 .
Bcr-Abl KD mutations are the most extensively investigated mechanism of resistance to imatinib, but they are not the only one. Actually, the frequency by which mutations have been implicated in imatinib resistance is different in the different phases of CML, 18 for a detailed review). It is also conceivable that, in a proportion of cases, more than one factor may cooperate to determine the resistance phenotype. We cannot even exclude that, in some patients, mutations may be simple 'bystanders'. This is unlikely in the presence of mutations highly insensitive to imatinib and for which a molecular mechanism of resistance has been posited (e.g., T315I, P-loop mutations, F359V), but might be the case for those less frequent mutations we have more limited knowledge on.
Therefore we recommend a change in therapy always to be triggered by concomitant evidence of failure or suboptimal response to imatinib. It is also important to bear in mind that, whatever the actual contribution of a mutation to the resistant phenotype is, its presence by itself should not be overlooked: mutations may be a sign of genetic instability, and genetic instability is the engine of disease evolution towards a more aggressive phenotype.
Optimization of CML treatment is a continuous process. Knowledge is still accumulating and the therapeutic scenario is still evolving. Nilotinib and dasatinib have just become available for newly diagnosed CML. In case of wider use of these TKIs in the first-line setting, the clinical impact of Bcr-Abl KD mutations would probably change profoundly.
These recommendations might be perceived as provisional under some aspects -but we think they can provide a valuable aid to clinicians in advising patients and managing current CML treatment. For In case of hematologic or cytogenetic failure Consider high dose imatinib* or dasatinib or nilotinib For personal use only. on July 15, 2017. by guest www.bloodjournal.org From
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